# Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

> **NCT02258529** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 10 (actual)

## Conditions studied

- Follicular Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Idelalisib
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT02258529
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-14
- **Primary completion:** 2016-04-12
- **Final completion:** 2016-05-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258529, "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02258529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*